CoChat
Sign Up
Cited by 59

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)

Hullon, Darshan, Subeh, Ghasaq K., Volkova, Yelizaveta, Janiec, Karolina, Trach, Adam, Mnevets, Ruslan·2025·Cardiovascular Diabetology
DOI 10.1186/s12933-025-02607-wPMC PMC11806760
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-025-02607-w

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These observations suggest that semaglutide may rapidly improve disease trajectory through cardiometabolic mechanisms independent of weight loss.

    “These observations suggest that semaglutide may rapidly improve disease trajectory through cardiometabolic mechanisms independent of weight loss, although the underlying pathophysiology requires further investigation.48-52”

    From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [52]

    The 'Data from clinical studies' section (page unavailable) reports that semaglutide improved HFpEF-related measures and reduced cardiovascular events, supporting the possibility of an improved disease trajectory. It does not establish that these benefits occur rapidly or independently of weight loss; the reported HFpEF improvements included weight loss and were assessed over 52 weeks. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America. J Card Fail. 2023;29(10):1412–51. · DOI
  2. Adamczak DM, Oduah MT, Kiebalo T, Nartowicz S, Bęben M, Pochylski M, Ciepłucha A, Gwizdała A, Lesiak M, Straburzyńska-Migaj E. Heart failure with preserved ejection fraction—a concise review. Curr Cardiol Rep. 2020. https://doi.org/10.1007/s11886-020-01349-3. · DOI
  3. Heinzel FR, Shah SJ. The future of heart failure with preserved ejection fraction. Herz. 2022;47:308–23. https://doi.org/10.1007/s00059-022-05124-8. · DOI
  4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEJM. 2006. https://doi.org/10.1056/NEJMoa052256. · DOI
  5. Stoicescu L, Crisan D, Morgovan C, Avram L, Ghibu S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int J Mol Sci. 2024;25(2):794. · DOI
  6. Abebe TB, Gebreyohannes EA, Tefera YG, Abegaz TM. Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. BMC Cardiovasc Disord. 2016;16(1):232. · DOI
  7. Capone F, Nambiar N, Schiattarella GG. Beyond weight loss: the emerging role of incretin-based treatments in cardiometabolic HFpEF. Curr Opin Cardiol. 2024;39:148–53. · DOI
  8. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003;83(1):59–115. · DOI · Paper page
  9. Qi XL, Stewart DJ, Gosselin H, Azad A, Picard P, Andries L, et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation. 1999;100(12):1338–45. · DOI
  10. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure—PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/10851216/
  11. Chu GX, Ling Q, Guo ZG. Effects of endocardial endothelium in myocardial mechanics of hypertrophied myocardium of rats. Zhongguo Yao Li Xue Bao. 1995;16(4):352–6.
  12. The pathomorphological alterations of endocardial endothelium in experimental diabetes and diabetes associated with hyperlipidemia—PubMed [cited 2024 Jul 24]. Available from: https://pubmed.ncbi.nlm.nih.gov/8777284/
  13. Gevaert AB, Shakeri H, Leloup AJ, Van Hove CE, De Meyer GR, Vrints CJ, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. Circ Heart Fail. 2017;10(6):e003806. · DOI · Paper page
  14. Lam CSP, Brutsaert DL. Endothelial dysfunction. J Am Coll Cardiol. 2012;60(18):1787–9. · DOI
  15. Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy—PubMed [cited 2024 Jul 24]. Available from: https://pubmed.ncbi.nlm.nih.gov/10769288/
  16. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota—PubMed. [cited 2024 Jul 24]. Available from: https://pubmed.ncbi.nlm.nih.gov/17404159/
  17. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2008;53:1119–26. https://doi.org/10.1016/j.jacc.2008.11.051. · DOI
  18. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin null, Newby DE, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertens Dallas Tex 1979. 2006;48(4):602–8. · DOI
  19. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012. https://doi.org/10.1016/j.jacc.2012.07.036. · DOI
  20. Sucato V, Evola S, Novo G, Sansone A, Quagliana A, Andolina G, et al. Angiographic evaluation of coronary microvascular dysfunction in patients with heart failure and preserved ejection fraction. Microcirc N Y N. 1994;22(7):528–33. · DOI
  21. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/25552356/
  22. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005. https://doi.org/10.1161/01.CIR.0000155615.68924.B3. · DOI
  23. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010. https://doi.org/10.1016/j.jacc.2010.03.077. · DOI
  24. Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(10):1130–43. · DOI
  25. Lin X, Wu G, Wang S, Huang J. The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis. Heart Fail Rev. 2023;29:405–16. · DOI
  26. Berndt J, Ooi SL, Pak SC. What is the mechanism driving the reduction of cardiovascular events from glucagon-like peptide-1 receptor agonists?-A mini review. Molecules. 2021;26(16):4822. · DOI
  27. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968–78. · DOI
  28. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2020;42(2):101–32. · DOI · Paper page
  29. Fatima A, Maryam A, Nadeem MS, Asmat KN. GLP-1 receptor agonists: a new frontier in combating metabolic liver disease complications. Aliment Pharmacol Ther. 2024;60:1499–500. · DOI
  30. Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions. JACC Heart Fail. 2019;7(2):87–97. · DOI
  31. Inciardi RM, Mantovani A, Targher G. Non-alcoholic fatty liver disease as an emerging risk factor for heart failure. Curr Heart Fail Rep. 2023;20(4):308–19. · DOI
  32. Kucsera D, Ruppert M, Sayour NV, Tóth VE, Kovács T, Hegedűs ZI, et al. NASH triggers cardiometabolic HFpEF in aging mice. GeroScience. 2024;46(5):4517–31. · DOI
  33. Zafar Y, Rashid AM, Siddiqi AK, Ellahi A, Ahmed A, Hussain H, et al. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022;46(7):101970. · DOI
  34. Badmus OO, Hinds TD, Stec DE. Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease. Curr Hypertens Rep. 2023;25(8):151–62. · DOI
  35. Wood M, Kennedy AG, Khan S, Hitt JR, Davis K, Reddy SS, et al. Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: a retrospective cohort study. J Pharm Pract. 2024;37(6):1297–302. · DOI
  36. Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med. 2024;16: e244661.
  37. Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(2):180–91. · DOI
  38. Yang Z, Tian R, Zhang XJ, Cai J, She ZG, Li H. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front Cardiovasc Med. 2023;12(9):1120085. · DOI
  39. Arriola-Montenegro J, Beas R, Cerna-Viacava R, Chaponan-Lavalle A, Hernandez Randich K, Chambergo-Michilot D, et al. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol. 2023;15(7):328–41. · DOI
  40. Gad AI, Ibrahim NF, Almadani N, Mahfouz R, Nofal HA, El-Rafey DS, et al. Therapeutic effects of semaglutide on nonalcoholic fatty liver disease with type 2 diabetes mellitus and obesity: an open-label controlled trial. Diseases. 2024;12(8):186. · DOI
  41. Kanbay M, Copur S, Guldan M, Ozbek L, Mallamaci F, Zoccali C. Glucagon and glucagon-like peptide-1 dual agonist therapy: a possible future towards fatty kidney disease. Eur J Clin Invest. 2025;55(1):e14330. · DOI
  42. Yen FS, Hsu CC, Wei JCC, Tsai FJ, Huang Y, Yu TS, et al. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024;79(11):1017–23. · DOI
  43. Albogami Y, Cusi K, Daniels MJ, Wei YJJ, Winterstein AG. Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care. 2021;44(6):1344–52. · DOI
  44. Wang W, Mei A, Qian H, Li D, Xu H, Chen J, et al. The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis. 2023;18:129–37. · DOI
  45. Kantreva K, Katsaounou P, Saltiki K, Trakada G, Ntali G, Stratigou T, et al. The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function. Endocrine. 2024. https://doi.org/10.1007/s12020-024-04033-6. · DOI
  46. Fandiño J, Toba L, González-Matías LC, Diz-Chaves Y, Mallo F. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci Rep. 2020;10(1):18091. · DOI
  47. Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503–11. · DOI
  48. Balk-Møller E, Windeløv JA, Svendsen B, Hunt J, Ghiasi SM, Sørensen CM, et al. Glucagon-like peptide 1 and atrial natriuretic peptide in a female mouse model of obstructive pulmonary disease. J Endocr Soc. 2020;4(1):034. · DOI
  49. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5–12. · DOI · Paper page
  50. Del Turco S, Gaggini M, Daniele G, Basta G, Folli F, Sicari R, et al. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. Curr Pharm Des. 2013;19(13):2420–31. · DOI
  51. Hu Y, Liu J, Wang G, Xu Y. The effects of exenatide and metformin on endothelial function in newly diagnosed type 2 diabetes mellitus patients: a case-control study. Diabetes Ther. 2018;9(3):1295–305. · DOI
  52. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model. Diabetes Vasc Dis Res. 2013;10(4):353–60. · DOI · Paper page
  53. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59–66. · DOI · Paper page
  54. Maxwell MA, Muscat GEO. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal. 2006;4:e002. · DOI
  55. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels—PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/22155457/
  56. Luo X, Hu Y, He S, Ye Q, Lv Z, Liu J, et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation. Arch Biochem Biophys. 2019;15(671):203–9. · DOI
  57. Onuma H, Inukai K, Kitahara A, Moriya R, Nishida S, Tanaka T, et al. The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells. Biochem Biophys Res Commun. 2014;451(2):339–44. · DOI
  58. Chang W, Zhu F, Zheng H, Zhou Z, Miao P, Zhao L, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019;116:73–9. · DOI
  59. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2292–301. · DOI
  60. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107(10):1255–62. · DOI
  61. Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, et al. Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. Diabetes Metab Res Rev. 2017;33(8):e2925. · DOI
  62. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030–7. · DOI · Paper page
  63. Yue W, Li Y, Ou D, Yang Q. The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. 2019;71(9):1347–54. · DOI
  64. Jensen DM, Skovsted GF, Bonde MFB, Bentzon JF, Rolin B, Franck G, et al. Semaglutide treatment attenuates vessel remodelling in ApoE-/- mice following vascular injury and blood flow perturbation. Atheroscler Plus. 2022;49:32–41. · DOI
  65. Eriksson L, Saxelin R, Röhl S, Roy J, Caidahl K, Nyström T, et al. Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury. J Vasc Res. 2015;52(1):41–52. · DOI
  66. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun. 2011;405(1):79–84. · DOI
  67. Conceição G, Heinonen I, Lourenço AP, Duncker DJ, Falcão-Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found. 2016;24(4):275–86.
  68. Valero-Muñoz M, Backman W, Sam F. Murine models of heart failure with preserved ejection fraction: a “fishing expedition.” JACC Basic Transl Sci. 2017;2(6):770–89. · DOI
  69. Rutledge C, Enriquez A, Redding K, Lopez M, Mullett S, Gelhaus SL, et al. Liraglutide protects against diastolic dysfunction and improves ventricular protein translation. Cardiovasc Drugs Ther. 2023. · DOI
  70. Banks TE, Rajapaksha M, Zhang LH, Bai F, Wang NP, Zhao ZQ. Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension. Eur J Pharmacol. 2022;15(927): 175048. · DOI
  71. Durak A, Turan B. Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts. J Physiol Biochem. 2023;79(2):297–311. · DOI
  72. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diabetes Vasc Dis Res. 2013;10(1):72–7. · DOI
  73. Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Heart Fail Rev. 2021;26(5):1151–8. · DOI
  74. Huixing L, Di F, Daoquan P. Effect of glucagon-like peptide-1 receptor agonists on prognosis of heart failure and cardiac function: a systematic review and meta-analysis of randomized controlled trials. Clin Ther. 2023;45(1):17–30. · DOI
  75. Wong SY, Lee A, Sia AHJ, Wo YJ, Teo YH, Teo YN, et al. Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials. Cardiovasc Drugs Ther. 2022;38:371–89. · DOI
  76. Zhang Y, Yang D, Jia Q, Yan J, An F. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: an updated systematic review and meta-analysis. Diabetes Obes Metab. 2024;26:2401–11. https://doi.org/10.1111/dom.15557. · DOI · Paper page
  77. Yagi K, Imamura T, Tada H, Chujo D, Liu J, Shima Y, et al. Diastolic cardiac function improvement by liraglutide is mainly body weight reduction dependent but independently contributes to B-type natriuretic peptide reduction in patients with type 2 diabetes with preserved ejection fraction. J Diabetes Res. 2021;2021:8838026. · DOI
  78. Temporelli PL. Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction. Eur Heart J Suppl. 2024;26(Supplement_1):127–530. · DOI
  79. Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-Nóvoa F, et al. Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. J Clin Endocrinol Metab. 2023;109(1):4–9. · DOI

Cited by

Sorted by citations

Metadata

Authors
Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R.
Venue
Cardiovascular Diabetology
Publisher
Springer Science and Business Media LLC
Published
2025-02-07
Volume
24
Issue
1
ISSN
1475-2840
DOI
10.1186/s12933-025-02607-w
PMC
PMC11806760
Cited by
59
References
14
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review